Market Overview

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance


Six New Biotechnology Companies Added to the Index

Loncar Investments, LLC today announced the result of the semi-annual
rebalance and reconstitution of the Loncar
Cancer Immunotherapy Index
, a stock index of top companies
developing cancer immunotherapy treatments and discovering new ways to
use the body's immune system to fight cancer.

The Committee has added Arcus Biosciences (NYSE:RCUS), Fate
Therapeutics (NASDAQ:FATE), Mirati Therapeutics (NASDAQ:MRTX),
MorphoSys (NASDAQ:MOR), Sorrento Therapeutics (NASDAQ:SRNE) and
Zymeworks (NYSE:ZYME) to the index.

In addition, the Committee has decreased the target number of index
components from 30 to 25 in order to 1) strengthen the index's liquidity
profile by boosting the market cap of the smallest component and 2)
lower the index's exposure to smaller companies that have not yet
demonstrated proof of concept in early clinical trials.

The additions replace Agenus (NASDAQ:AGEN), Armo Biosciences (Nasdaq: ARMO), Bellicum Pharmaceutials (NASDAQ:BLCM), Celldex Therapeutics
(NASDAQ:CLDX), Idera Pharmaceuticals (NASDAQ:IDRA), Incyte Corporation
(NASDAQ:INCY), Inovio Pharmaceuticals (NASDAQ:INO), Jounce
Therapeutics (NASDAQ:JNCE), Pieris Pharmaceuticals (NASDAQ:PIRS),
NantKwest (NASDAQ:NK) and NewLink Genetics (NASDAQ:NLNK).

"The significant changes to the index this period reflect the speed with
which the science of immunotherapy is moving," said Brad Loncar, CEO of
Loncar Investments and Chairman of the index committee. "Our index is
designed to evolve with the science and highlight technologies at the
forefront of research. We welcome these new additions that bring
innovative and unique approaches to the field."

Effective this week, all index holdings have been rebalanced to hold
equal weight. The index is rebalanced and reconstituted semi-annually.
The next rebalance will occur on December 18, 2018.

Loncar Investments is an official partner of the Cancer
Research Institute
, the world's longest running nonprofit
organization dedicated exclusively to harnessing the immune system's
power to conquer all cancers. To learn about how to donate to CRI,
please visit here.

Why immunotherapy: Cancer immunotherapy has become an important
sector in the biotechnology space and is changing the way many cancers
are treated. While traditional medicines like chemotherapies often give
cancer a broad punch, the benefit of using immunotherapy is derived from
the immune system's dynamic nature and the way it can more precisely be
tailored to fight a patient's disease.

About the index: The Loncar Cancer Immunotherapy Index is an
equal-weighted index of top immunotherapy companies rebalanced and
reconstituted on a semi-annual basis. Price and return data are
independently calculated on a daily basis by Indxx, LLC. Additional
information can be found at the index's dedicated website,

Index provider: Loncar Investments, LLC is committed to making
the biotechnology space more approachable to a wider range of investors.
It incorporates extensive research into biotech companies and
technologies to develop stock market indexes that are focused on precise
investment opportunities. The company is principally owned by biotech
investor and analyst Brad Loncar.

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial